For the best user experience please use a browser to proceed.

ORPH - Orphazyme A/S price and analysis

Fundamentals:
Basic Info:
  • Market Cap: 186.40M
  • Exchange: NASDAQ
  • Shares Float: 28,143,200
  • Shares Outstanding: 34,952,200
  • Revenue Per Employee:
Advanced Info:
  • ROE ttm: -188.10 %
  • ROA ttm: -75.80 %
  • Beta: 0.641
  • EPS: None
  • Debt Ratio ttm: 0.25
  • Debt / Equity Ratio ttm: 0.33
  • Payout Ratio ttm:
Cash Ratios:
  • Cash Ratio ttm: 4.36
  • Current Ratio ttm: 4.7
  • Quick Ratio ttm: 4.47
Key Ratios:
  • P/E trailing 12 month:
  • P/E forward:
  • P/E trailing 12m high:
  • P/E trailing 12m low:
  • P/S trailing 12 month:
  • EV/S trailing 12 month:
  • P/B trailing 12 month: 1.88
  • PEG ratio:
Shorts:
  • Shares Short: 873,200
  • Shares Short Prev Month: 731,750
  • Days to Cover: 0.03
  • Short Percent Float: 3.10 %
  • Short Percent Outstanding: 3.00 %
Ownership:
  • Percent Insiders:
  • Percent Institutions: 0.94 %
Margins:
  • Gross Profit Margin ttm:
  • EBITDA Margin ttm:
  • Operating Margin ttm:
  • Net Income Margin ttm:
Target Prices:
  • Target Price High: 1 USD
  • Target Price Low: 1 USD
  • Target Price Mean: 1 USD
  • Number of Analysts: 2
Key Prices:
  • 52 Week High: 23.9
  • 52 Week Low: 4.96
  • 50 Day Moving Average: 7.59
  • 200 Day Moving Average: 9.67
Dividends:
  • Trailing Dividend yld:
  • Forward Dividend yld:
  • Payout Ratio:
  • Ex-Dividend date: None
Current Quarter Estimates:
  • Current Quarter EPS estimate: -0.7 ~ -0.7 (2020-09-30)
  • Current Quarter revenue estimate: 0 ~ 0
As of: 2021-07-24
Latest News:
Bragar Eagel & Squire, PC Reminds Investors That ClassGlobeNewswire2021-07-22 00:00:00 EDT
Why Orphazyme Stock Skyrocketed 24.6% TodayThe Motley Fool2021-06-23 16:22:03 EDT
ORPHAZYME A/S DK 1 (1TB.BE)Yahoo Finance2021-02-09 10:56:00 EDT
Orphazyme A/S (ORPH)Yahoo Finance2021-02-01 00:00:00 EDT
Orphazyme A/S ADRWall Street Journal2021-01-29 08:00:00 EDT
(1O3AB.NX)Yahoo Finance2021-01-21 03:15:00 EDT
Major shareholder announcementBusiness Insider2021-01-18 15:57:00 EDT
Orphazyme provides regulatory update on arimoclomol for NPCBusiness Insider2021-01-18 15:48:00 EDT
Orphazyme A/SMarketWatch2021-01-12 00:00:00 EDT
ORPH.OQ - Orphazyme A/S Profile | ReutersReuters2021-01-10 21:11:00 EDT
Click to expand the area.
Income Statements:
ORPH - Orphazyme A/S Income Statement
Unit: (thousand)2020Q4
Qtr Revenue0
Rev Growth yoy %
Cost of Revenue0
Gross Profit0
Gross Profit MgnNaN %
Research and Development97152.00
Selling & Marketing Expense0.00
General & Administrative Expense84337.50
Interest Expense
Operating Expense0.00
Operating Income-181489.50
Operating Mgn-Infinity %
Net Income-190915.50
Net Income Mgn-Infinity %
Generated by @earningsfly with ❤️
Cashflow Statements:
ORPH - Orphazyme A/S Cashflow Statement
Unit: (million)2020Q4
Operating Cashflows-167.45
Financing Cashflows233.24
Investing Cashflows-1.67
Total Capital Expenditures0.60
Changes In Cash0
Free Cash flow0
Generated by @earningsfly with love ❤️
Balance Sheets:
ORPH - Orphazyme A/S Balance Sheet
Unit: (milllion)2020Q4
Total Assets822.49
Intangible Assets12.45
Goodwill0.00
Current Assets783.66
Current Cash726.93
Account Receivables0.00
Inventory0.00
Total Liabilities201.97
Account Payables0.00
Short Term Debt33.35
Long Term Debt23.83
Current Ratio4.70
Debt Ratio0.07
Debt/Equity Ratio0.09
Generated by @earningsfly with ❤️
Latest Posts:
Not available at this time..
Orphazyme A/S
(NASDAQ:ORPH)
Orphazyme A/S

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical developmen...
CEO: Kim Stratton(Oct 2019~)
Sector: Other
Industry: Other
Full Time Employees: 141
Next Earnings Date: 2021-08-24
Keywords: Orphazyme
Summary and stock analysis:
  • Return on equity score:
  • Return on assets score:
  • P/B ratio score:
Basic Info:
  • Market Cap: 186.40M
  • Exchange: NASDAQ
  • Shares Float: 28,143,200
  • Shares Outstanding: 34,952,200
  • Revenue Per Employee:
Advanced Info:
  • ROE ttm: -188.10 %
  • ROA ttm: -75.80 %
  • Beta: 0.641
  • EPS: None
  • Debt Ratio ttm: 0.25
  • Debt / Equity Ratio ttm: 0.33
  • Payout Ratio ttm:
Cash Ratios:
  • Cash Ratio ttm: 4.36
  • Current Ratio ttm: 4.7
  • Quick Ratio ttm: 4.47
Key Ratios:
  • P/E trailing 12 month:
  • P/E forward:
  • P/E trailing 12m high:
  • P/E trailing 12m low:
  • P/S trailing 12 month:
  • EV/S trailing 12 month:
  • P/B trailing 12 month: 1.88
  • PEG ratio:
Shorts:
  • Shares Short: 873,200
  • Shares Short Prev Month: 731,750
  • Days to Cover: 0.03
  • Short Percent Float: 3.10 %
  • Short Percent Outstanding: 3.00 %
Ownership:
  • Percent Insiders:
  • Percent Institutions: 0.94 %
Margins:
  • Gross Profit Margin ttm:
  • EBITDA Margin ttm:
  • Operating Margin ttm:
  • Net Income Margin ttm:
Target Prices:
  • Target Price High: 1 USD
  • Target Price Low: 1 USD
  • Target Price Mean: 1 USD
  • Number of Analysts: 2
Key Prices:
  • 52 Week High: 23.9
  • 52 Week Low: 4.96
  • 50 Day Moving Average: 7.59
  • 200 Day Moving Average: 9.67
Dividends:
  • Trailing Dividend yld:
  • Forward Dividend yld:
  • Payout Ratio:
  • Ex-Dividend date: None
Current Quarter Estimates:
  • Current Quarter EPS estimate: -0.7 ~ -0.7 (2020-09-30)
  • Current Quarter revenue estimate: 0 ~ 0
As of: 2021-07-24
Click to expand the area.
Analyst Consensus:
ORPH - Orphazyme A/S Analyst Opinions
Target high: 1 USD
Target low: 1 USD
Average: 1 USD based on 2 analysts as of 2021-07-03

Generated by @earningsfly with ❤️
Analyst Trends:
ORPH - Orphazyme A/S Analyst Trends
Target high: 1 USD
Target low: 1 USD
Average: 1 USD based on 2 analysts as of 2021-07-03
Generated by @earningsfly with ❤️
Website Ranking Analysis:
ORPH - Orphazyme A/S  World Website Ranking Analysis
Generated by @earningsfly with ❤️
Google Trends Analysis:
ORPH - Orphazyme A/S Google 5-year Trends Analysis
Keyword: Orphazyme
Generated by @earningsfly with ❤️
Employees Analysis:
ORPH - Orphazyme A/S Employees Analysis
Generated by @earningsfly with ❤️
Institution & Insiders Analysis:
ORPH - Orphazyme A/S Ownership Analysis
Generated by @earningsfly with ❤️
Debt & Cash Analysis:
ORPH - Orphazyme A/S Cash and Debt Analysis(unit: milllion DKK)
Generated by @earningsfly with ❤️
Short Analysis:
ORPH - Orphazyme A/S Shorts Analysis
Generated by @earningsfly with 🚀
Margins and Revenue:
ORPH - Orphazyme A/S Revenue and Margins
Generated by @earningsfly with 🚀
Income Statement Analysis:
ORPH - Orphazyme A/S Income Statement
Unit: (thousand)2020Q4
Qtr Revenue0
Rev Growth yoy %
Cost of Revenue0
Gross Profit0
Gross Profit MgnNaN %
Research and Development97152.00
Selling & Marketing Expense0.00
General & Administrative Expense84337.50
Interest Expense
Operating Expense0.00
Operating Income-181489.50
Operating Mgn-Infinity %
Net Income-190915.50
Net Income Mgn-Infinity %
Generated by @earningsfly with ❤️
Earnings Estimate Analysis:
ORPH - Orphazyme A/S EPS Estimates
Current Qtr Estimate (dashed line): -0.7
Generated by @earningsfly with ❤️
Cashflow Analysis:
ORPH - Orphazyme A/S Cashflow Statement
Unit: (million)2020Q4
Operating Cashflows-167.45
Financing Cashflows233.24
Investing Cashflows-1.67
Total Capital Expenditures0.60
Changes In Cash0
Free Cash flow0
Generated by @earningsfly with love ❤️